Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20935635 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Chen S, et al. (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 12, 1108-14 20935635
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T345-p - EZH2 (human) ▲
Orthologous residues
EZH2 (human): T345‑p, EZH2 (mouse): T345‑p, EZH2 (rat): T345‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  293T (epithelial), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK2 (human)
KINASE CDK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) siRNA inhibition of enzyme, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme
KINASE CDK2 (human) siRNA inhibition of enzyme, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
p21Cip1 (human) decrease
p27Kip1 (human) decrease
siRNA decrease siRNA CDK1 and CDK2
roscovitine siRNA augment treatment-induced decrease
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell growth, altered, cell motility, altered, transcription, altered

K28-m3 - H3 (human) ▲
Orthologous residues
H3 (human): K28‑m3, H3 (mouse): K28‑m3, H3 iso2 (mouse): K28‑m3, H3 iso3 (mouse): K28‑m3, H3 (rat): K28‑m3, H3 iso3 (rat): K28‑m3, H3 (pig): K28‑m3, H3 (chicken): K28‑m3, H3 (cow): K28‑m3
Characterization
 Methods used to characterize site in vivo:  modification-specific antibody
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
METHYLTRANSFERASE EZH2 (human) siRNA inhibition of enzyme


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.